AbbVie slammed over ‘drip feed’ of Imbruvica patents

AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica (ibrutinib), a new report has revealed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Health campaigners call for greater checks on AbbVie/Allergan merger

20 February 2020 Trade unions and consumer groups have urged the Federal Trade Commission to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.

Big Pharma

AbbVie’s pending Allergan takeover moves closer after drug divestments

28 January 2020 Biopharmaceutical company AbbVie’s pending purchase of pharmaceutical company Allergan has moved a step closer, following the latter’s agreement to divest treatments brazikumab and Zenpep, in a development meant to satisfy antitrust regulations in the US.

Americas

PTAB cancels Imbruvica patent claims in blow for AbbVie

25 September 2020 The US Patent Trial and Appeal Board has invalidated parts of an AbbVie patent covering blood disease drug Imbruvica.